ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE

Key Points

• ADAR1 Capital Management acquired 216,752 Monte Rosa Therapeutics shares worth approximately $5.25 million, while institutional investors collectively own nearly 80% of GLUE.
• Monte Rosa reported a quarterly loss of $0.43 per share, missing estimates by $0.05, and revenue of $8.97 million versus the $12.91 million consensus; the company continues to post significant negative margins.
• Investor sentiment remains mixed but broadly positive: analysts maintain a consensus “Moderate Buy” rating with a $28.50 price target, while Monte Rosa has begun a Phase 2 prostate cancer trial for its lead program.

ADAR1 Capital Management LLC purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 216,752 shares of the company's stock, valued at approximately $5,245,000. ADAR1 Capital Management LLC owned about 0.25% of Monte Rosa Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. acquired a new position in Monte Rosa Therapeutics in the 2nd quarter worth about $165,603,000. State Street Corp raised its position in Monte Rosa Therapeutics by 148.9% in the fourth quarter. State Street Corp now owns 2,107,480 shares of the company's stock valued at $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $18,399,000. AQR Capital Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company's stock valued at $5,791,000 after purchasing an additional 1,054,406 shares in the last quarter. Finally, Braidwell LP bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $14,870,000. Institutional investors and hedge funds own 79.96% of the company's stock.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $14.56 on Wednesday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $25.77. The stock has a 50 day simple moving average of $19.98 and a two-hundred day simple moving average of $18.74. The company has a market cap of $1.24 billion, a P/E ratio of -8.27 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). The business had revenue of $8.97 million for the quarter, compared to the consensus estimate of $12.91 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. On average, research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.32 earnings per share for the current year.

Insider Activity at Monte Rosa Therapeutics

In other news, insider Sharon Townson sold 6,000 shares of the company's stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the transaction, the insider owned 67,845 shares in the company, valued at approximately $1,581,466.95. This represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Filip Janku sold 5,407 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the transaction, the insider directly owned 60,612 shares in the company, valued at $1,484,994. This trade represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 79,603 shares of company stock valued at $1,725,081. 6.40% of the stock is currently owned by company insiders.

Monte Rosa Therapeutics News Roundup

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Phase 2 prostate cancer trial has begun. Monte Rosa dosed the first patient in the MODeFIRe-1 study, evaluating MRT-2359 in combination with apalutamide in patients with androgen-receptor mutation-positive metastatic castration-resistant prostate cancer. The milestone advances the company’s lead clinical program, although it does not yet provide efficacy data. Monte Rosa Announces First Patient Dosed in MODeFIRe-1
• Positive Sentiment: Analyst sentiment strengthened. TD Cowen upgraded Monte Rosa to “strong buy,” adding to the bullish tone surrounding the company’s pipeline and development prospects. Zacks report on TD Cowen upgrade
• Positive Sentiment: Guggenheim reaffirmed its “buy” rating and set a $28 price target. That target implies substantial upside from the referenced $14.56 share price, signaling confidence in Monte Rosa’s longer-term value. Benzinga report on Guggenheim rating
• Neutral Sentiment: Short-interest data showed no measurable short position. The report listed short interest at zero shares and a zero-day days-to-cover ratio, but the stated percentage change was unavailable, limiting the usefulness of this update as a trading signal.

Analysts Set New Price Targets

Several research firms have recently issued reports on GLUE. Wedbush lowered their price objective on Monte Rosa Therapeutics from $37.00 to $27.00 and set an "outperform" rating for the company in a research note on Monday, August 3rd. Wells Fargo & Company cut their target price on shares of Monte Rosa Therapeutics from $29.00 to $27.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. Weiss Ratings lowered shares of Monte Rosa Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Tuesday, August 11th. Zacks Research raised shares of Monte Rosa Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Guggenheim restated a "buy" rating and issued a $28.00 price objective on shares of Monte Rosa Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company's main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source